UK Court of Appeal Confirms Moderna鈥檚 EP'949 Patent is Valid and Infringed by Pfizer/BioNTech
Moderna (NASDAQ:MRNA) has secured a significant legal victory as the UK Court of Appeal upheld the validity of its EP'949 patent and confirmed that it is infringed by Pfizer/BioNTech's COVID-19 vaccine Comirnaty庐. This marks the first global second-instance decision validating one of Moderna's core mRNA patents.
The ruling reinforces the initial High Court decision from July 2024, which Pfizer/BioNTech had appealed. Additionally, Moderna has achieved favorable legal outcomes in other European jurisdictions: Germany's Regional Court found patent infringement by Pfizer/BioNTech, and the European Patent Office (EPO) upheld EP'949's validity in opposition proceedings, though appeals are pending in both cases.
Moderna (NASDAQ:MRNA) ha ottenuto una vittoria legale significativa, poich茅 la Corte d'Appello del Regno Unito ha confermato la validit脿 del suo brevetto EP'949 e ha stabilito che il vaccino COVID-19 Comirnaty庐 di Pfizer/BioNTech ne viola i diritti. Si tratta della prima decisione di secondo grado a livello globale che convalida uno dei brevetti chiave di Moderna sull'mRNA.
La sentenza rafforza la decisione iniziale dell'Alta Corte del luglio 2024, contro cui Pfizer/BioNTech aveva presentato ricorso. Inoltre, Moderna ha ottenuto esiti legali favorevoli in altre giurisdizioni europee: il Tribunale regionale tedesco ha riconosciuto la violazione del brevetto da parte di Pfizer/BioNTech e il Ufficio Europeo dei Brevetti (EPO) ha confermato la validit脿 dell'EP'949 durante il procedimento di opposizione, anche se sono ancora in corso appelli in entrambi i casi.
Moderna (NASDAQ:MRNA) ha logrado una importante victoria legal, ya que el Tribunal de Apelaci贸n del Reino Unido confirm贸 la validez de su patente EP'949 y estableci贸 que la vacuna COVID-19 Comirnaty庐 de Pfizer/BioNTech la infringe. Esta es la primera decisi贸n de segunda instancia a nivel mundial que valida una de las patentes clave de Moderna sobre ARN mensajero.
El fallo refuerza la decisi贸n inicial del Tribunal Superior de julio de 2024, contra la cual Pfizer/BioNTech hab铆a apelado. Adem谩s, Moderna ha obtenido resultados legales favorables en otras jurisdicciones europeas: el Tribunal Regional de Alemania encontr贸 la infracci贸n de la patente por parte de Pfizer/BioNTech, y la Oficina Europea de Patentes (EPO) confirm贸 la validez de la EP'949 en procedimientos de oposici贸n, aunque a煤n est谩n pendientes apelaciones en ambos casos.
氇崝雮�(狈础厂顿础蚕:惭搁狈础)臧� 鞓侁淡 頃唽氩曥洂鞐愳劀 EP'949 韸鬼棃鞚� 鞙犿毃靹膘潉 鞚胳爼氚涥碃, 頇旍澊鞛�/氚旍澊鞓れ棓韰岉伂鞚� COVID-19 氚膘嫚 旖旊雮橅嫲庐臧� 鞚措ゼ 旃暣頄堧嫟電� 韺愱舶鞚� 氚涭晞 欷戩殧頃� 氩曥爜 鞀闺Μ毳� 瓯半憪鞐堨姷雼堧嫟. 鞚措姅 氇崝雮橃潣 頃奠嫭 mRNA 韸鬼棃 欷� 頃橂倶鞐� 雽�頃� 鞝� 靹戈硠鞝侅溂搿� 霊� 氩堨Ц 鞁笁鞐愳劀 鞙犿毃靹膘潉 鞚胳爼氚涭潃 觳� 靷鞛呺媹雼�.
鞚措矆 韺愱舶鞚� 頇旍澊鞛�/氚旍澊鞓れ棓韰岉伂臧� 頃唽頃� 2024雲� 7鞗� 瓿犽摫氩曥洂鞚� 齑堦赴 韺愱舶鞚� 臧曧檾頃橂姅 瓴瓣臣鞛呺媹雼�. 霕愴暅 氇崝雮橂姅 鞙犽熃鞚� 雼るジ 甏�頃犼秾鞐愳劀霃� 鞙犽Μ頃� 氩曥爜 瓴瓣臣毳� 鞏混棃鞀惦媹雼�: 霃呾澕 歆�氚� 氩曥洂鞚� 頇旍澊鞛�/氚旍澊鞓れ棓韰岉伂鞚� 韸鬼棃 旃暣毳� 鞚胳爼頄堦碃, 鞙犽熃 韸鬼棃觳�(EPO)鞚� EP'949 韸鬼棃鞚� 鞙犿毃靹膘潉 鞙犾頄堨溂雮� 霊� 靷贝 氇憪 頃唽臧� 歆勴枆 欷戩瀰雼堧嫟.
Moderna (NASDAQ:MRNA) a obtenu une victoire juridique importante, la Cour d'appel du Royaume-Uni ayant confirm茅 la validit茅 de son brevet EP'949 et 茅tabli que le vaccin COVID-19 Comirnaty庐 de Pfizer/BioNTech enfreint ce brevet. Il s'agit de la premi猫re d茅cision mondiale en deuxi猫me instance validant l'un des brevets cl茅s de Moderna sur l'ARNm.
Cette d茅cision renforce le jugement initial de la Haute Cour de juillet 2024, contre lequel Pfizer/BioNTech avait fait appel. De plus, Moderna a obtenu des r茅sultats juridiques favorables dans d'autres juridictions europ茅ennes : le tribunal r茅gional allemand a reconnu la violation du brevet par Pfizer/BioNTech, et l'Office europ茅en des brevets (OEB) a confirm茅 la validit茅 de l'EP'949 lors de proc茅dures d'opposition, bien que des appels soient en cours dans les deux cas.
Moderna (NASDAQ:MRNA) hat einen bedeutenden rechtlichen Erfolg erzielt, da das Berufungsgericht des Vereinigten K枚nigreichs die G眉ltigkeit seines EP'949-Patents best盲tigt und festgestellt hat, dass der COVID-19-Impfstoff Comirnaty庐 von Pfizer/BioNTech dieses Patent verletzt. Dies ist die erste weltweit rechtskr盲ftige Entscheidung der zweiten Instanz, die eines von Modernas zentralen mRNA-Patenten best盲tigt.
Das Urteil st盲rkt die urspr眉ngliche Entscheidung des High Court vom Juli 2024, gegen die Pfizer/BioNTech Berufung eingelegt hatte. Zudem hat Moderna in weiteren europ盲ischen Gerichtsbarkeiten positive rechtliche Ergebnisse erzielt: Das Landgericht Deutschland stellte eine Patentverletzung durch Pfizer/BioNTech fest, und das Europ盲ische Patentamt (EPA) best盲tigte die G眉ltigkeit von EP'949 in Einspruchsverfahren, wobei in beiden F盲llen Berufungen anh盲ngig sind.
- UK Court of Appeal confirms validity of Moderna's EP'949 patent and its infringement by Pfizer/BioNTech
- First global second-instance decision validating Moderna's core mRNA patent
- Additional favorable rulings in Germany and from European Patent Office
- Strong legal precedent established for protecting Moderna's mRNA technology
- Ongoing appeals in German and EPO cases create continued legal uncertainty
CAMBRIDGE, MA / / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna's EP'949 patent.
This decision affirms the High Court's initial ruling from July 2024 that the EP'949 patent is valid and infringed by Pfizer/BioNTech's COVID-19 vaccine, Comirnaty庐, which was subsequently appealed by Pfizer/BioNTech. With this ruling, the UK becomes the first jurisdiction globally to issue a second-instance decision confirming the validity of one of Moderna's core mRNA patents. The High Court's finding of infringement was not disputed by Pfizer/BioNTech on appeal.
"Moderna is pleased that the Court of Appeal has upheld the High Court's finding that the EP'949 patent is valid and infringed by Pfizer/BioNTech," said Moderna Chief Legal Officer Shannon Thyme Klinger. "Moderna will continue to pursue and enforce its patent rights globally to protect its innovative mRNA technology."
Elsewhere in Europe, recent legal developments have further strengthened Moderna's intellectual property portfolio:
In Germany, the Regional Court found that Pfizer and BioNTech infringed Moderna's modified mRNA patent and confirmed Moderna's right to seek damages. An appeal is pending.
The European Patent Office (EPO) upheld the validity of EP'949 in opposition proceedings, further reinforcing the patent's strength. An appeal is pending.
European patent EP'949 relates to chemically modified mRNA, one of Moderna's foundational technologies that enables the development of mRNA-based medicines.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Moderna Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's plans to enforce its patent rights globally, including through seeking damages for infringement. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
Moderna Contacts
Media:
Chris Ridley
Head of Global Media Relations
+1 617-800-3651
[email protected]
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
[email protected]
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
FAQ
What did the UK Court of Appeal rule regarding Moderna's patent dispute with Pfizer/BioNTech?
How does the UK Court ruling impact Moderna's patent rights globally?
What other legal victories has Moderna (MRNA) secured in Europe regarding their patents?
What technology does Moderna's EP'949 patent cover?
Will Pfizer/BioNTech face damages for patent infringement?
